Skip to main content
SpringerLink
Log in

Disease Management Update

  • From the World Literature
  • Published:
Disease Management & Health Outcomes

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. PharmacoEconomics & Outcomes News provides comprehensive coverage of the biomedical literature on health economics and outcomes research, and summarizes information selected from over 1600 journals.

  2. Gastric banding, variable gastric banding, vertical banded gastroplasty or gastric bypass

  3. The study was supported in part by a grant from Hoffmann-La Roche Ltd., Switzerland.

  4. Costs were presented in 1996 values and discounted at a rate of 3% per annum.

  5. Physician fees were not included

  6. The study was supported in part by a grant from GlaxoSmithKline, US.

  7. Costs (2000 values) were those related to prescribed medication, physician visits, laboratory tests, procedures, x-rays and hospitalizations.

  8. As measured using the St George’s Respiratory Questionnaire and the Short-Form 36

  9. Costs (2000 values) were those associated with hospitalization, ED visits, physician, social-support and home-nurse visits, prescription drugs, telephone calls and transportation services, and were assessed from the perspective of the public health insurer.

  10. Year 2000 values, discounted at 5% per annum

  11. The six geographic regions of the world, as defined by the WHO, are the African region, the region of the Americas, the eastern Mediterranean region, the European region, south-east Asia and the western Pacific region.

  12. The program was administered by a pharmacoeconomics and outcomes research fellow.

  13. Payments (2001 values) included those for Medicare, patient copayments and other third-party payments.

  14. Costs (1998 Canadian dollars) were those associated with personnel, retina specialist and technician services, transportation and equipment. All costs were calculated from a healthcare system’s perspective and were discounted at 5% per annum.

  15. Costs (2000 values) were those associated with endoscopic screening, ERCP-related complications, pancreatectomy, medical care and indirect pancreatic cancer care, and were discounted at 3% per annum. Costs were calculated primarily from a third-party payor perspective.

  16. The study was sponsored by an unrestricted grant from Sanofi-Synthelabo and Bristol-Myers Squibb.

  17. very cost effective = interventions that gain each year of healthy life at a cost less than gross domestic product per head; cost effective = interventions that gain each year of healthy life at a cost of one to three times gross domestic product per head

  18. DOTS = directly observed treatment-short course; DOTS-plus = directly observed use of second-line antituberculosis drugs for 18–24 months

  19. The study was supported in part by Bristol-Myers Squibb and Parke-Davis.

  20. Costs (2000 values) were those associated with hospitalization, outpatient care, laboratory tests and procedures, medications, participant time spent travelling, shopping, cooking and attending appointments, exercise courses and equipment, food and transportation, and time lost from usual activity due to morbidity or mortality.

  21. National Asthma Education and Prevention Project

  22. daily use of inhaled corticosteroids, ownership of a peak flow meter, previously being tested for allergies and adequate knowledge of asthma self-management

References

2. Hospitalization Costs Not Reduced with Surgery in Obesity

  • Ågren G, Narbro K, Jonsson E, et al. Cost of in-patient care over 7 years among surgically and conventionally treated obese patients. Obes Res Dec 2002; 10: 1276–83.

    Article  PubMed  Google Scholar 

3. Education Needed to Increase’ Flu Vaccination Rates Among Elderly

  • Zimmerman RK, Santibanez TA, Janosky JE, et al. What affects influenza vaccination rates among older patients? An analysis from inner-city, suburban, rural, and Veterans Affairs practices. Am J Med Jan 2003; 114: 31–8.

    Article  PubMed  Google Scholar 

4. Hospitalist Care Reduces Resource Use, Costs in the US

  1. Meltzer D, Manning WG, Morrison J, et al. Effects of physician experience on costs and outcomes on an academic general medicine service: results of a trial of hospitalists. Ann Int Med 3 Dec 2002; 137: 866–74.

    PubMed  Google Scholar 

  2. American College of Physicians-American Society of Internal Medicine. The who, what, when, where, whom, and how of hospitalist care. Ann Int Med 3 Dec 2002; 137: 930–1.

    Google Scholar 

5. Collaborative Care Intervention Warranted for Panic Disorder in the US

  • Katon WJ, Roy-Byrne P, Russo J, et al. Cost-effectiveness and cost offset of a collaborative care intervention for primary care patients with panic disorder. Arch Gen Psych Dec 2002; 59: 1098–1104.

    Article  Google Scholar 

6. Home Hospitalization Cuts Costs in COPD

  • Hernandez C, Casas A, Escarrabill J, et al. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. Eur Resp J Jan 2003; 21: 58–67.

    Article  CAS  Google Scholar 

7. Cancer DM Program Saves US Millions in Third Year

  • Quality oncology claims $4.3 million savings for Fla. plan. Dis Manage News 25 Feb 2003; 3 & 8.

8. Polio Vaccination “a Good Economic Investment”

  • Khan MM, Ehreth J. Costs and benefits of polio eradication: a long-run global perspective. Vaccine Jan 2003; 21: 702–5.

    Article  PubMed  Google Scholar 

9. Drug Assistance Program Pays Off From Hospital Perspective

  • Coleman CI, Reddy P, Quercia RA, et al. Cost-benefit analysis of a pharmacy-managed medication assistance program for hospitalized indigent patients. Am J Health Syst Pharm 15 Feb 2003; 60: 378–82.

    PubMed  Google Scholar 

10. Major Depression Increases Costs Among US Elderly with Diabetes

  • Finkelstein EA, Bray JW, Chen H, et al. Prevalence and costs of major depression among elderly claimants with diabetes. Diab Care Feb 2003; 26: 415–20.

    Article  Google Scholar 

11. Camera-Based Screening for Diabetic Retinopathy Well Worth it in Canada

  • Maberley D, Walker H, Koushik A, et al. Screening for diabetic retinopathy in James Bay, Ontario: a cost-effectiveness analysis. CMAJ 21 Jan 2003; 168: 160–4.

    PubMed  Google Scholar 

12. Chemotherapy Use Diverges from US Breast Cancer Guidelines

  • Du XL, Key CR, Osborne C, et al. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Int Med 21 Jan 2003; 138: 90–7.

    Google Scholar 

13. Endoscopic Screening Worth It for Pancreatic Cancer in the US

  • Rulyak SJ, Kimmey MB, Veenstra DL, et al. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc Jan 2003; 57: 23–9.

    Article  PubMed  Google Scholar 

14. Statins Underused for Stroke, TIA in Austria

  • Lalouschek W, Lang W, Greisenegger S, et al. Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischrmic attack. Stroke Jan 2003; 34: 105–10.

    Article  PubMed  CAS  Google Scholar 

15. Health Interventions “Very Cost Effective” in Less-Developed Countries

  • Murray CJL, Lauer JA, Hutubessy RCW, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 1 Mar 2003; 361: 717–25.

    Article  PubMed  Google Scholar 

16. Is DOTS-Plus Worth It for TB in Developing Countries?

  • Sterling TR, Lehmann HP, Frieden TR. Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis. BMJ 15 Mar 2003; 326: 574–7.

    Article  PubMed  Google Scholar 

17. Opioid Analgesics Underused for Neuropathic Pain in Canada

  • Gilron I, Bailey JM. Trends in opioid use for chronic neuropathic pain: a survey of patients pursuing enrollment in clinical trials. Can J Anaesth Jan 2003; 50: 42–7.

    Article  PubMed  Google Scholar 

18. Cost Analysis of Modest Interventions to Prevent Type 2 Diabetes

  1. Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diab Care Jan 2003; 26: 36–47.

    Google Scholar 

  2. Teutsch S. The cost of preventing diabetes: what do we know and what do we need to know? Diab Care Jan 2003; 26: 238–9.

    Article  Google Scholar 

19. Pharmacy Claims Data Improve Physician Quality of Care

  • Bieszk N, Patel R, Heaberlin A, et al. Detection of medication nonadherence through review of pharmacy claims data. Am J Health Syst Pharm 15 Feb 2003; 60: 360–6.

    PubMed  Google Scholar 

20. Guideline Compliance Poor in Antipsychotic Prescribing

  • Sernyak MJ, Dausey D, Desai R, et al. Prescribers’ nonadherence to treatment guidelines for schizophrenia when prescribing neuroleptics. Psychiatr Serv Feb 2003; 54: 246–8.

    Article  PubMed  Google Scholar 

21. Asthma Severity Underestimated, Treatment Suboptimal in the US

  • Wolfenden LL, Diette GB, Krishnan JA, et al. Lower physician estimate of underlying asthma severity leads to undertreatment. Arch Int Med 27 Jan 2003; 163: 231–6.

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Disease Management Update. Dis-Manage-Health-Outcomes 11, 337–344 (2003). https://doi.org/10.2165/00115677-200311050-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200311050-00007

Keywords

Search

Navigation